Oppenheimer Reiterates Buy Rating on Definium Therapeutics
Oppenheimer maintains a buy rating on Definium Therapeutics with a $60 price target, a 42.42% upside from the current price.
Key Points
- Oppenheimer reiterated its buy rating on Definium Therapeutics, Inc. (DFTX) with a $60 price target on June 22, 2026.
- Oppenheimer's $60 price target implies 42.42% upside from Definium Therapeutics, Inc.'s ($DFTX) current $42.13 share price.
- Shares of DFTX traded near $24.48 on Monday, with a market cap of approximately $2.67 billion and a 52-week range of $6.35 to $26.25.
- Insider buying was reported with key executives acquiring shares, and analysts maintain positive outlooks with a consensus strong buy rating.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 22, 2026, Oppenheimer reiterated its buy rating on Definium Therapeutics, Inc. (NasdaqGS: DFTX) and set a price target of $60. Shares of Definium traded near $24.48 on Monday.
Oppenheimer vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Definium Therapeutics, Inc. Stock Up 2.8%
Shares of Definium Therapeutics, Inc. (DFTX) were trading around $24.48 on Monday. The company, which operates in the biotechnology industry, has a market capitalization of about $2.67 billion. It has a 52-week low of $6.35 and a high of $26.25. The stock's 50-day moving average is $22.61, while the 200-day moving average is $16.28. The forward P/E ratio is not meaningful as the company is not currently profitable.
$DFTX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Definium Therapeutics, Inc.
Several insiders at Definium Therapeutics made notable stock purchases recently. On June 22, 2026, Chief Executive Officer Robert Barrow acquired 375,000 shares. Chief Medical Officer Daniel Karlin bought 100,000 shares, while Chief Financial Officer Brandi Roberts and Chief Legal Officer Mark Sullivan each purchased 62,500 shares. Chief Commercial Officer Matthew Wiley also acquired 62,500 shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 22, 2026, Oppenheimer maintained its buy rating on Definium Therapeutics with a $60 price target. Leerink Partners also maintained a buy rating, setting a $52 target on the same day. Earlier, on June 16, 2026, Canaccord Genuity maintained its buy rating with a $38 target. The consensus among analysts is a strong buy, with an average target price of $39.87 from 15 analyst opinions.
About Definium Therapeutics
Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New York, NY. The company focuses on developing novel treatments for brain health disorders. Its lead products include DT120, in phase 3 trials for anxiety and depressive disorders, and DT402, in phase 2a trials for autism spectrum disorder. Led by CEO Robert Barrow, Definium was formerly known as Mind Medicine (MindMed) Inc. until it rebranded in January 2026.
Bottom Line
Oppenheimer's reaffirmation of a buy rating with a $60 target highlights the positive sentiment among analysts towards Definium Therapeutics. Investors keep an eye on such ratings as they provide insights into potential stock performance. However, it's crucial to remember that these ratings are based on past data and projections, not a guarantee of future performance.
Get Definium Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DFTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.